2024

1. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

   Journal of Hepatology, Vol. 80, Núm. 3, pp. 419-430

2. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

   Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

3. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

   JHEP Reports, Vol. 6, Núm. 7